Abstract
Healthcare expenditures for cancer account for a low share of total healthcare expenditures, compared to the relative burden of the disease. The share has also not changed very much over the last decades. Cost for cancer drugs has increased as a share of total expenditures, but this has been offset by a reduction of inpatient hospital care for cancer. Accounting for the cost of cancer should not be limited to healthcare expenditures. Resources are also used for public and private care of cancer patients outside the healthcare sector, for example for palliative care. Informal care by family and friends is an important complement to professional care, and estimates indicate that this amounts to between half and one-third of the costs of formal care. Indirect costs related to the loss of production for persons with cancer are estimated to be of the same magnitude as the direct healthcare expenditures. Indirect costs related to premature mortality dominate the estimate of indirect costs, but those costs have declined over time, despite increasing incomes, due to the reduction in mortality due to cancer in the economically active age groups. Estimates of indirect costs due to morbidity are uncertain and vary significantly between published studies. A full accounting of the costs of cancer should include an estimate of the health burden of cancer. Loss of quality-adjusted life expectancy (QALY) can be measured and valued based on the willingness to pay for a QALY. Such estimates are possible to derive from decisions about allocating resources for cancer. There are few estimates of these costs, but available studies indicate that the intangible costs of lost QALY are by far the dominating cost of cancer. The value for policy-making of costs of cancer estimates increases when results with consistent methods and data are available that allow comparisons between countries and over time. The evidence about the cost of cancer is still limited, but when current scientific progress produces an increasing number of new options for prevention, diagnosis and treatment, studies of the cost of cancer become increasingly important to inform decisions about resource allocation.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Antoñanzas F, Oliva J, Velasco M, Zozaya N, Lorente R, López-Bastida J (2006) Costes directos e indirecto del cáncer en España (direct and indirect costs of cancer in Spain). Cuad Económicos de ICE 72:280–309
Brundin L, Kobelt G, Berg J, Capsa D, Eriksson J (2017) European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe: results for Sweden. Mult Scler Aug 23(2_suppl):179–191
Dakin H, Devlin N, Feng Y, Rice N, O’Neill P, Parkin D (2015) The influence of cost- effectiveness and other factors on nice decisions. Health Econ 24(10):1256–1271
Greenberg D, Earle C, Fang CH, Eldar-Lissai Adi, Neumann PJ (2010) When is cancer care cost-effective? a systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst 102:82–88
Hodgson TA, Meiners MR (1982) Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 60(3):429–462
Howard DH, Bach PB, Berndt ER, Conti RM (2015) Launch prices for 58 anticancer drugs approved in the US 1995–2013. J Econ Perspect 29:139–162
Jönsson B, Lindgren P, Hofmarcher T, Wilking N (2016a) A pan-European comparison regarding patient access to cancer drugs revisited. IHE, Lund, Sweden
Jönsson B, Lindgren P, Hofmarcher T, Wilking N (2016b) The cost and burden of cancer in the European Union. Eur J Cancer 66:162–170
Lidgren M, Wilking N, Jonsson B (2007) Cost of breast cancer in Sweden in 2002. Eur J Health Econ 8(1):5–15
Luengo-Fernandez R, Leal J, Gray A, Sullivan R (2013) Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 14(12):1165–1174
Lundquist A, Andersson E, Steen-Karlsson K (2016) Kostnaden för cancer i Sverige idag och 2040. IHE Report 2016:1
Meropol NJ, Schulman Kevin A (2012) Cost of cancer care: issues and implications. J Clin Oncol 2007 25:180–186. See also Lakdawalla DN, Romley JA, Sanchez Y, Maclean JR, Penrod JR, Philipson T, How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. Health Aff 31(4):676–682
Oslo Economics (2016) Kreft i Norge: Kostnader for patienterne, helsetjenesten og samfunnet. Report 16 June, Oslo Economics and BMS
Ramsey S, Blough D, Kirchhoff A, et al (2013) Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood) 32(6):1143–52. See also https://www.cancer.gov/about-cancer/managing-care/financial-toxicity-hp-pdq
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Jönsson, B. (2019). Cost of Cancer: Healthcare Expenditures and Economic Impact. In: Walter, E. (eds) Regulatory and Economic Aspects in Oncology. Recent Results in Cancer Research, vol 213. Springer, Cham. https://doi.org/10.1007/978-3-030-01207-6_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-01207-6_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-01206-9
Online ISBN: 978-3-030-01207-6
eBook Packages: MedicineMedicine (R0)